Introduction
Mammalian Bcl-2 family proteins share homology that is principally clustered within conserved Bcl-2 homology domains (BH1, BH2, BH3 and BH4), but could also contain a long flexible loop (LOOP), a pore-forming domain consisting of a-5 and a-6 helices, and a carboxyterminal hydrophobic transmembrane domain (TM) responsible for their sublocalization to subcellular organelles, including the mitochondria, endoplasmic reticulum and nucleus. Members of this family of proteins are critical regulators of apoptosis that either promote cell survival or facilitate cell death. The antiapoptotic members of the family are multidomain proteins (e.g. Bcl-2, Bcl-xL, Bcl-w, Mcl-1), while the proapoptotic members are subdivided into two classes: multidomain proteins that contain Bcl-2 homology (BH) domains 1-3 (e.g. Bax, Bak), and BH3-only proteins constituted of a unique BH3 motif (e.g. Bad, Bid, Bik, Bim, Hkr) (Kroemer, 1997; Reed, 1997; Chao and Korsmeyer, 1998; Adams and Cory, 2001) .
The various forms of Bcl-2 family proteins possess unique combinations of structure-function domains that determine their capacity to interact with each other and with other proteins, forming a complex network of homo-and hetero-oligomers upon stimulation (Yang and Korsmeyer, 1996; Kroemer, 1997; Reed, 1997; Chao and Korsmeyer, 1998; Kroemer and Reed, 2000) . The localization of these proteins at the outer mitochondrial membrane indicates that they influence the opening and/ or closing of mitochondrial megachannels by so-called permeability transition pores (mPTP) (Bernardi et al., 1994; Zoratti and Szabo, 1996) as well as the release of apoptogenic activators from the mitochondria, including apoptosis-inducing factor (Susin et al., 1996 (Susin et al., , 1999b , cytochrome c (Kluck et al., 1997a, b; Yang et al., 1997a) , Diablo/Smac (Du et al., 2000; Verhagen et al., 2000) , EndoG Parrish et al., 2001) , Omi/HtrA2 (Suzuki et al., 2001) , and some procaspases such as procaspase-9 and -2 (Susin et al., 1999a) . The formation of homo-and hetero-complexes between proteins of the Bcl-2 family and those containing only a BH3 domain is well-described, and recent studies have shown that the multidomain Bax and Bak proteins are essential for cell death, acting downstream of the BH3 domain-only members Wei et al., 2001; Zong et al., 2001 ).
Current views on the role of the BH3 domain-only proteins encompass not only the binding and sequestration of antiapoptotic members like Bcl-2 and Bcl-xL, but also the binding and activation of proapoptotic members like Bax and Bak. In turn, upon activation, these form high molecular weight oligomer complexes and clusters in the mitochondrial outer membrane (Franke and Cantley, 1997; Hsu et al., 1997; Wolter et al., 1997; Goping et al., 1998; Gross et al., 1998; Li et al., 1998; Luo et al., 1998; Griffiths et al., 1999; Nechushtan et al., 1999; Eskes et al., 2000; Korsmeyer et al., 2000; Wei et al., 2000; Antonsson et al., 2001; Cheng et al., 2001; Jia et al., 2001; Makin et al., 2001; Mikhailov et al., 2001; Nechushtan et al., 2001; Zhao et al., 2001) . These complexes then possibly form highconductance pore channels by themselves (Muchmore et al., 1996; Antonsson et al., 1997; Minn et al., 1997; Schendel et al., 1997) and/or in association with yet unknown partners to beget the so-called mitochondrial apoptosis-induced channel (Pavlov et al., 2001) and/or modulate the opening/closing of mPTP in cooperation with adenine nucleotide translocator protein (ANT) (Marzo et al., 1998) and the mitochondrial porin channel or voltage-dependent anion channel (VDAC1) (Shimizu et al., 1999 . Activated proapoptotic proteins like Bax accelerate VDAC1 opening in a manner that permits cytochrome c to pass directly through, while the BH4-containing antiapoptotic proteins Bcl-xL and Bcl-2 impede such opening (Shimizu et al., 1999 .
In addition, initial studies have demonstrated interaction of Bcl-xL, Bcl-2 and Boo/Diva with Ced-4/Apaf-1 Huang et al., 1998; Inohara et al., 1998; Pan et al., 1998; Song et al., 1999) . In the mitochondrial pathway of caspase activation, Apaf-1 binds to procaspase-9 in the presence of dATP and cytochrome c, and this interaction is mediated by caspase recruitment domains found on the two proteins (Qin et al., 1999; Zhou et al., 1999) . Complex formation between Apaf-1 and procaspase-9 zymogen leads to caspase-9 cleavage and activation, probably through autoproteolytic processing, and caspase-9 in turn directly activates caspase-3 and -7 (Li et al., 1997; Zou et al., 1997; Srinivasula et al., 1998) . Bcl-xL, Bcl-2 and Boo/Diva binding to Apaf-1 appears to inhibit Apaf-1 oligomerization and caspase-9 activation Huang et al., 1998; Inohara et al., 1998; Pan et al., 1998; Song et al., 1999) , situations similar to that described in C. elegans, whereas the prosurvival Ced-9 binds and sequesters Ced-4, but also forms a ternary complex with Ced-3, thereby preventing Ced-4 oligomerization and Ced-3 activation (Chinnaiyan et al., 1997; Seshagiri and Miller, 1997; Spector et al., 1997; Wu et al., 1997a, b; Chaudhary et al., 1998) . However, other investigations have been unable to demonstrate either an association of Bcl-xL or Bcl-2 with Apaf-1 or cellular co-localization of these proteins (Moriishi et al., 1999; Conus et al., 2000; Haraguchi et al., 2000; Hausmann et al., 2000; Newmeyer et al., 2000) . Whether other antiapoptotic Bcl-2 family members bind and/or sequester Apaf-1 remains an unresolved question.
In this paper, we report the identification and characterization of Bcl-xES (extra short), a novel Bcl-x member expressed in various human tissues and cancer cell lines. Bcl-xES has a unique structure compared to others, and contains BH4 and BH2 domains, sequences of a-6 helices and a COOH-terminal hydrophobic transmembrane anchor domain, but lacks the BH1, BH3 and flexible LOOP domains and sequences corresponding to a-5 helices. In a yeast two-hybrid system, Bcl-xES interacted with most Bcl-2 family members, including those containing only a BH3 domain, and also with the Ced-4 homolog Apaf-1. Bcl-xES deletion mutants indicated that BH4 and BH2 are required for these interactions. In addition, our data suggest that Bcl-xES delays drug-induced apoptosis by disturbing the formation of Bax oligomers and preventing cytochrome c release and Apaf-1 oligomerization, but also by directly interacting with Apaf-1 and inhibiting procaspase-9 activation, blocking the mitochondrial apoptogenic proteolytic cascade and cell death.
Results

Bcl-xES, a unique BH4-, BH2-and transmembrane anchor domain-containing protein
Among all the Bcl-2 family members, Bcl-xES contains a unique combination of BH4, BH2 and TM domains (Figure 1 ). First identified and cloned from human promyelocytic HL-60 cells, bcl-xES mRNA expression was investigated in various human cell lines and tissues by reverse transcriptase-polymerase chain reaction (RT-PCR) and, in some specimens, by ribonucleotidase protection assay. Table 1 (upper panel) summarizes the detection of Bcl-xES mRNA compared to Bcl-xL and Bcl-xS in a series of human cancer cell lines and normal or cancerous human tissues of various origins. Bcl-xES was detected in most cancer cell lines and tissues with the exception of normal human breast, ovary, testis and lung. The relative amount of Bcl-xES was semiquantitated and normalized to the amount of Bcl-xL by autoradiograph densitometry. In the panel of cancer cell lines analysed, the relative ratios (bcl-xES to bcl-xL) were found to be highly heterogenous among samples (n ¼ 19), ranging from 0 to 1 and 0.74 to 1. In the panel of human tissues analysed, Bcl-xES levels were much lowered than Bcl-xL levels, with a few exceptions (bone marrow samples #1 and #3), as shown in the representative autoradiographs (Table 1, lower panel) .
To investigate whether Bcl-xES is expressed at the protein level, we first analysed total cellular extracts obtained from HL-60, U-937 and Namalwa cells by Western immunoblotting, using Bcl-x-specific monoclonal antibodies generated from amino acids 18-233 of rat Bcl-xL. These extracts were prepared in the presence of a cocktail of protease inhibitors and lactacystin, a potent proteosome activity inhibitor. We detected three Bcl-xES, a BH4-and BH2-containing antiapoptotic protein E Schmitt et al bands corresponding to approximately Mr 26 000, Mr 17 000 and Mr 13 000 kDa, most probably representing Bcl-xL, Bcl-xS and Bcl-xES, respectively (Figure 2a) . Subcellular fractionation and Western immunoblot analysis indicated that in Namalwa cells, endogenous Bcl-xES protein was expressed in mitochondrial, cytosolic and nuclear fractions (Figure 2b ). To investigate the activity and mode of action of Bcl-xES on cell death, first, Bcl-xES cDNA was subcloned in a modified pCEP4 expression vector that contained consensus Kozak and hemagglutinin epitope tag sequences (HAtag) (Schmitt et al., 1998a (Schmitt et al., , b, 2000 . After transfection, a stable Namalwa variant line that expresses HA-Bcl-xES was selected under hygromycin B1. Control Namalwa (Figure 2c ).
Effect of HA-Bcl-xES on the kinetics of apoptosis induced by cytotoxic agents
Previous studies have shown that 20-S-camptothecin (CPT), a DNA topoisomerase I inhibitor, etoposide (VP-16), a DNA topoisomerase II inhibitor, cis-platinum (II) diamine dichloride (cisPT), a DNA adductinducing agent, and tumor necrosis factor-alpha (TNFa) elicit morphological changes, caspase activation and internucleosomal DNA fragmentation associated with apoptosis in Namalwa cells (Schmitt et al., 1998a (Schmitt et al., , b, 2000 . To assess the effect of overexpressing Bcl-xES in these cells, the kinetics of DNA fragmentation associated with apoptosis induced by these agents were monitored and quantitated by filter DNA elution assay. Namalwa cells overexpressing Bcl-xES presented significant modulation of and protection against apoptosis evoked by these cytotoxic drugs (Figure 3 ). Compared to the reported effect of Bcl-xL in Namalwa cells (Schmitt et al., 1998b) , Bcl-xES seems to have a less pronounced protective action after various treatments. However, it is difficult to really compare the effect of the two proteins, simply because the Bcl-xL and Bcl-xES expression levels achieved in these cells after transfection are different. Translocation of mitochondrial intermembrane protein cytochrome c to the cytosol is associated with anticancer drug-induced apoptosis. To define the effect of Bcl-xES in the mitochondrial pathway of caspase activation, first, cytochrome c release was monitored after CPT treatment. Bcl-xES delayed cytochrome c release into the cytosol of transfected Namalwa cells, compared to wild-type cells, for at least 4 h after 0.1 mM CPT, and sustainingly for 4 h after 1.0 mM CPT (Figure 4a ). Cytochrome c release allows Apaf-1/ procaspase-9 oligomerization and interaction that result in the rapid activation of caspase-9, which, in turn, directly activates effector caspase-3 and -7 (Li et al., 1997; Zou et al., 1997; Srinivasula et al., 1998) . To study the consequence of cytochrome c release inhibition in Namalwa-Bcl-xES cells, we monitored the kinetics of caspase-9 (LEHDase) and caspase-3-and -7-like (DEVDase) activities. Both LEHDase and DEVDase activities were retarded in Namalwa cells overexpressing BclxES compared to wild-type cells after CPT treatments (Figure 4b ). The kinetics of DNA fragmentation presented in Figure 3 are in accordance with those of cytochrome c release and caspase activities, and were further visualized by agarose gel electrophoresis after CPT treatment (Figure 4c ). Altogether, these results Bcl-xES was immunodetected, using anti-Bcl-x-specific monoclonal antibody. Cytochrome c and Lamin B were monitored as controls. Visualization was performed by enhanced chemiluminescence reaction and film exposure. (c) Subcellular localization of HABcl-xES in transfected Namalwa cells. Subcellular extracts were prepared from control Namalwa (N) and stable Namalwa cells transfected by electroporation with pCEP4-HA-Bcl-xES and selected at 1.5 mg/ml hygromycin B (ES), as described in Materials and methods. After SDS-PAGE and electrophoretic transfer, HABcl-xES protein was detected using anti-HA peptide monoclonal antibodies. Cytochrome c was monitored as control. Visualization was performed by enhanced chemiluminescence reaction and film exposure Bcl-xES, a BH4-and BH2-containing antiapoptotic protein E Schmitt et al indicated that Bcl-xES prevented cytochrome c release, subsequent caspase-9, -3 and -7 activation and DNA fragmentation.
Interaction of Bcl-xES with human Bcl-2 family members and Apaf-1
The affinity of Bcl-xES dimerization among various Bcl-2 family members and Apaf-1 was monitored in a yeast two-hybrid system. Transmembrane hydrophobic anchor sequences were removed from the cDNAs to promote their nuclear translocation, to avoid the toxicity of proapoptotic members in yeast cells, and to prevent unspecific interactions through their hydrophobic transmembrane domain. Interestingly, Bcl-xES interacted strongly with all family members tested, including BH3-only members and the Ced-4 homolog Apaf-1 (Figure 5a ). Most likely, the absence of BH1, BH3 and a-5 helices confers increased exposure of the BH2 and BH4 domains of the protein, compared to other Bcl-2 members like Bcl-xL or Bcl-2 that show multiglobular conformation. In addition, the ability of Bcl-xES to interact strongly with Apaf-1 seems specific, since we previously reported that a Bax isoform had no affinity for Apaf-1, in the same yeast two-hybrid system (Schmitt et al., 2000) . To further analyse these interactions, we first compared the ability of Bcl-xL to interact with Apaf-1 and a BH3-only protein in this yeast two-hybrid system, and we generated two Bcl-xES deletion mutants lacking either BH4 (Bcl-xESDBH4) or BH2 (Bcl-xESDBH2) ( Figure 5b ). In this two-hybrid system, Bcl-xL did not interact with Apaf-1, but rather with a BH3-only family member. Bcl-xES strongly interacted with Apaf-1, Bcl-xESDBH4 did not interact with Apaf-1, while Bcl-xESDBH2 showed a weak interaction with it. Interestingly, neither Bcl-xESDBH4 nor Bcl-xESDBH2 interacted with a BH3-only family member. These results suggested that BH4 is required for the Bcl-xES interaction with Apaf-1, while both BH4 and BH2 seem to be needed for Bcl-xES interaction with other Bcl-2 family members. The strong affinity of Bcl-xES for most Bcl-2 family members and Apaf-1 indicates that multiple interactions within cells could possibly account for the antiapoptotic effect of Bcl-xES.
Bcl-xES interferes with the formation of Bax oligomers after CPT treatment
To explore the mechanisms by which Bcl-xES prevented cytochrome c release from the mitochondria after CPT treatment, we monitored its effect on Bax activation and oligomer formation. Since Bcl-xES interacted strongly with multidomain and BH3 domain-only proapoptotic proteins in the yeast two-hybrid system, we postulated that such interactions in cells could interfere with and ; Bcl-xES-transfected Namalwa cells selected at 1.5 mg/ml hygromycin (closed circles). Mock vector-transfected Namalwa cells selected at 1.5 mg/ml hygromycin show similar sensitivity to control Namalwa cells Bcl-xES, a BH4-and BH2-containing antiapoptotic protein E Schmitt et al Figure 4 Cytochrome c release, caspase activation and oligonucleosome-sized DNA fragmentation after CPT treatment. (a) Cytochrome c release. Cytosolic S-100 and mitochondrial extracts were prepared from Namalwa and Namalwa/Bcl-xES-transfected cells at the indicated times (0, 4 h) after 30-min treatment with 0.1 mM CPT (left panel) or 1.0 mM CPT (right panel). Immunoblot analysis of cytochrome c was performed using anticytochrome c-specific antibodies and revealed by enhanced chemiluminescence and film exposure. (b) LEHDase and DEVDase activities. Namalwa and Namalwa/Bcl-xES-transfected cells were treated for 30 min with 0.1 mM (left panels) or 1.0 mM CPT (right panels). Cytosolic extracts were then prepared from Namalwa (open circles) and Namalwa/ Bcl-xES cells (closed circles) at the indicated times after treatment. LEHDase (upper panels) and DEVDase (lower panels) activities were monitored continuously at 371C by detecting fluorescence emission in the presence of Ac-LEHD-AFC and Ac-DEVD-AMC, respectively. Enzyme activities were measured as initial velocities and expressed as relative intensity/min/mg. Points represent the means7s.d. of three independent experiments. (c) Oligonucleosome-sized DNA fragmentation. At the indicated times after 30-min treatment with 0.1 mM (left panels) or 1.0 mM CPT (right panels), total DNA was extracted from Namalwa (upper panels) and Namalwa/Bcl-xES (lower panels) cells, and visualized after agarose gel electrophoresis and ethidium bromide staining delay Bax activation and oligomer formation after CPT treatment. To monitor the effect of Bcl-xES on Bax oligomerization, protein extracts obtained from control and CPT-treated cells were subjected to gel filtration chromatography. The elution profiles of Bax after CPT treatment in Namalwa cells showed a strong shift of the proteins toward fractions of higher molecular weight, compared to its detection in untreated control cells, as early as 2 h after 0.1 mM and 1.0 mM CPT (Figure 6a , upper panels). The shift of Bax toward fractions of higher molecular weight was even more dramatic after 1.0 mM CPT. In contrast, the elution profiles of Bax after similar treatment in Namalwa/Bcl-xES-transfected cells revealed much more moderate shifts toward fractions of higher molecular weight (Figure 6a , lower panels). In fact, the elution profiles of Bax in Namalwa/Bcl-xES after 1.0 mM CPT were more or less equivalent to those seen in Namalwa cells after 0.1 mM CPT, a 10-fold difference of CPT concentration. These results indicated that Bax formed high molecular weight oligomers very rapidly after DNA damage induced by CPT, an observation that correlates with the activation of apoptosis. In addition, Bcl-xES expression had a pronounced impact on the kinetics and amplitude of Bax oligomerization induced by CPT, in accordance with the Bcl-xES effect on cytochrome c release.
To further analyse the effect of Bcl-xES on Bax oligomerization, co-immunoprecipitation experiments were conducted to monitor if Bcl-xES binds to multidomain proapoptotic Bax in untreated and CPT-treated Namalwa cells. Mitochondria-enriched fractions were incubated with dithiobis[succinimidylpropionate] (DSP), a homobifunctional N-hydroxysuccinimide ester crosslinker, to stabilize protein interactions and to ease the detection of other proteins in Bcl-xES immunocomplexes. Higher amounts of Bax and Bak proteins were immunoprecipitated from mitochondrial extracts obtained 2 and 4 h after CPT treatment compared to untreated cells (Figure 6b ). These results suggested that the inhibition of Bax high molecular weight oligomerization, observed in Figure 6a , could be explained in part by the ability of Bcl-xES to bind Bax protein, thus averting its oligomerization. The interaction of Bcl-xES with Bak could potentially have a similar effect, obviating Bak oligomerization or Bax/Bak heteromerization.
Interaction of Bcl-xES with Apaf-1
Initial studies showed interactions between some antiapoptotic members of the Bcl-2 family, including BclxL, Bcl-2 and Diva with Ced4/Apaf 1 Huang et al., 1998; Inohara et al., 1998; Pan et al., 1998; Song et al., 1999) . However, contrasting observations have also been reported (Moriishi et al., 1999; Conus et al., 2000; Haraguchi et al., 2000; Hausmann et al., 2000; Newmeyer et al., 2000) . Interestingly, we noted a strong interaction between Bcl-xES and Apaf-1 in the yeast two-hybrid system ( Figure 5 ). To explore the possibility that Bcl-xES can interfere with Apaf-1 oligomerization in Namalwa cells, we first studied the effect of Bcl-xES on Apaf-1 oligomerization and procaspase-9 activation. Protein extracts were obtained from control and CPT-treated cells and subjected to gel filtration chromatography. To avoid Apaf-1 self-oligomerization during the lysis procedure, 10 mM adenosine 5 0 -O-(-3-thiotriphosphate) (ATP-gS) was added to the lysis buffer. In Namalwa cells, the elution profiles of Apaf-1 showed a prominent shift of the protein toward fractions of higher molecular weight 2 h after 0.1 mM CPT treatment (Figure 7a, upper panels) . Apaf-1 Figure 5 Interaction of Bcl-xES and deletion mutants in yeast two-hybrid assay. (a) Bcl-xES deleted of its transmembrane domain, Bcl-xES(DTM), was subcloned in two-hybrid plasmid pLexA vector. The Bcl-2 family members Bcl-xL (DTM), Bcl-xS (DTM), Bfl-1 (DTM), Bcl-2 (DTM), Bax-a (DTM), Bax-s (DTM), Bax-k (DTM), Bak (DTM), Bok (DTM), Bik (DTM), Bad and the human Ced-4 homologue Apaf-1 were subcloned in the two-hybrid plasmid pB42AD. Positive controls ( þ ) represent pLexA p53 and pB42 SV40 T, and negative controls (À) represent pLexA-lamin C and pB42 SV40 T. EGY 48 represents untransformed yeast cells. (b) Bcl-xES(DTM), Bcl-xL(DTM) and the deletion mutants BclxES(DBH4DTM) and Bcl-xES(DBH2DTM) were subcloned in twohybrid plasmid pLexA vector. Apaf-1, Bik(DTM) and Bad were subcloned in the two-hybrid plasmid pB42AD. Positive and negative controls are as above. In all cases, sequential transformations were conducted by the lithium acetate method in yeast strain EGY48, and the cells were plated on histidine/tryptophan/leucinedeficient (for LEU2 reporter gene assay) minimal SD induction/ selection media Bcl-xES, a BH4-and BH2-containing antiapoptotic protein E Schmitt et al oligomerization coincided with the appearance of active caspase-9 fragments (Figure 7a , upper panels). In contrast, in Namalwa/Bcl-xES-transfected cells, the elution profiles of Apaf-1 obtained after 0.1 mM CPT treatment showed neither Apaf-1 oligomerization nor procaspase-9 activation, even 4 h after drug treatment (Figure 7a , lower panels). When these cells were treated with 1.0 mM CPT, a sustaining amount of Apaf-1 protein shifted toward fractions of higher molecular weight, from 2 to 4 h after drug treatment (Figure 7a , lower panels). Also, Apaf-1 oligomerization was associated with the appearance of active caspase-9 fragments 4 h after drug treatment (Figure 7a , lower panels). Together, these experiments indicated that Bcl-xES modulated Apaf-1 oligomerization and procaspase-9 activation after CPT treatment.
To further analyse this effect of Bcl-xES, a series of co-immunoprecipitation experiments were performed Figure 6 Kinetics of Bax-a oligomer formation after CPT treatment. (a) FPLC elution profiles of Bax-a from Namalwa and Namalwa/Bcl-xES-transfected cells on Superose 6-HR 16/50, as described in Materials and methods. Cellular extracts were prepared at the indicated times from 5 Â 10 8 control and drug-treated Namalwa (upper panels) and control and drug-treated Namalwa/Bcl-xES (lower panels) cells at the indicated times after 0.1 and 1.0 mM CPT. The elution peaks of the molecular weight standards (kDa) are indicated by arrows. After chromatography, 80 ml of each fraction (numbers above each lane) was run on SDS-PAGE and electrotransferred. Immunoblots were revealed using anti-Bax polyclonal antibody and visualized by enhanced chemiluminescence and film exposure. (b) Mitochondria-enriched fractions were prepared, as described under Materials and methods, from control (0 h), 2-h and 4-h CPT-treated Namalwa/Bcl-xES cells, incubated with DSP crosslinker and lysed in 2% CHAPS-containing buffer. A 100-mg protein fraction was incubated with anti-HA antibodies. After capture of the immunocomplexes, the covalent bonds created by DSP were cleaved under reducing conditions and the immunoprecipitates were subjected to SDS-PAGE, and analysed by Western blotting with specific antibodies. Extraction and immunoprecipitation from mitochondria-enriched, untransfected Namalwa cells (Nam) and a whole cells extract obtained from Namalwa/Bcl-xES cells (extract) were used as negative and positive controls, respectively in control and CPT-treated Namalwa/Bcl-xES cells. BclxES was able to bind and to precipitate Apaf-1 (Figure 7b ). Apaf-1 binding to Bcl-xES remained constant for at least 6 h when Namalwa/Bcl-xES cells were treated with 0.1 mM CPT (Figure 7b, upper panels) , a condition where Bax oligomer formation, cytochrome c release, caspase activation and apoptosis were impaired in these cells. In contrast, Apaf-1 interaction with Bcl-xES was diminished when the cells were exposed to 1.0 mM CPT (Figure 7b, lower panels) , a condition where Bax oligomerization, cytochrome c release and caspase activation were observed, albeit attenuated when compared to untransfected cells. Thus, Bcl-xES binding to Apaf-1 could possibly interfere with its oligomerization, as well as procaspase-9 recruitment and activation, in addition to its prevention of Bax oligomerization and cytochrome c release. To test this possibility, we deployed a cell-free system in which procaspase-9 is activated by the addition of cytochrome c and dATP. Cell-free extracts were prepared from untreated U-937 cells, and caspase-9 activity was monitored with a fluorogenic peptide substrate in the absence or presence of various amounts of recombinant Bcl-xES protein deleted of its TM domain (Bcl-xES(DTM)). The addition of recombinant Bcl xES(DTM) induced dose-dependent inhibition of Ac-LEHD-AFC hydrolysis ( Figure 7c ). As a negative control, the addition of recombinant Bcl-xES(DTM) in cellular extracts obtained from apoptotic cells had no inhibitory effect on caspase activities (data not shown).
Discussion
Several iso-proteins of the Bcl-2 family, which either show similar or opposite effects, have been identified in mammalian cells. These include Bcl-2 (Bcl-2-a, -2) (Tsujimoto and Croce, 1986) , Bcl-x (Bcl-xL, -xS, -xb, -xg) (Boise et al., 1993; Yang et al., 1997b; Ban et al., 1998) , Bax (Bax-a, -b, -g, -d, -o, -e, -s) (Oltvai et al., 1993; Apte et al., 1995; He et al., 1998; Zhou et al., 1998; Shi et al., 1999; Schmitt et al., 2000) , Bim/Bod (Bim-L, -EL, -S, -a1, -a2, -b1, Àb2, -b3, -b4) (O'Connor et al., 1998; U et al., 2001), BNip1 (BNip-1, -1a, -1b, -1c) (Zhang et al., 1999) , Bok/Mtd (Hsu and Hsueh, 1998) and Bcl-g (Bcl-gL, -gS) (Guo et al., 2001) . In the present study, we noted that an apparant alternative spliced isoform of the Bcl-x gene, which encoded a protein containing only the BH4, BH2 and COOH-terminus hydrophobic transmembrane domains, behaves as an antiapoptotic family member. To the best of our knowledge, it is the only member of the family that shows this specific combination of BH2 and BH4 domains. The BH2 and BH4 domains of Bcl-2 and Bcl-xL are functional domains associated with their antiapoptotic activities. While BH2 is important for homo-and hetero-dimerization with other members of the Bcl family (Borner et al., 1994; Yin et al., 1994; Hanada et al., 1995; Hunter et al., 1996) , the BH4 domain is reported to be involved in the interaction between Bcl-2 and Bcl-xL with Raf-1, calcineurin and Ced-4/Apaf-1 (Wang et al., 1996; Shibasaki et al., 1997; Hu et al., 1998; Huang et al., 1998; Pan et al., 1998) . In addition, the BH4 domain is implicated in the modulation of VDAC1 activity . More recently, other investigators have revealed a role for the BH4 domain of Bcl-2 in modulating IkBa through an unknown mechanism that could involve ANT (de Moissac et al., 1999; Bottero et al., 2001) .
The expression profile of bcl-xES mRNA is relatively similar to that of bcl-xL and bcl-xS, but seems to vary in the breast, ovary, testis and lung. Bcl-xES protein is also observed among diverse human leukemic cell lines, although at a lower level compared to Bcl-xL. However, the expression level of the protein was stabilized by the addition of the proteosome inhibitor lactacystin, suggesting that Bcl-xES could have a high turnover in these cells (data not reported). This indicates that the physiological role of the various isoforms in modulating apoptosis might be highly tissue-and environmentspecific.
Following CPT treatment, Bcl-xES overexpression delayed cytochrome c release, a common observation with antiapoptotic members of the Bcl-2 family. Most likely, Bcl-xES, that showed strong interactions in yeast two-hybrid assay, binds and inhibits proapoptotic members, including those containing only a BH3 domain that would be activated after CPT-induced DNA damage. In a recent study, we found that multidomain and BH3 domain-only proteins are induced rapidly and translocated to the mitochondria within 1-2 h after CPT treatment in Namalwa cells. The ratio between anti-and proapoptotic members of the Bcl-2 families is an important mechanism controlling cell death. Upon cell death stimulation, translocation and oligomerization of proapoptotic members to the mitochondria switch the mitochondrial equilibrium toward apoptosis (Yang and Korsmeyer, 1996; Kroemer and Reed, 2000) . Perhaps the degree of protection conferred by Bcl-xES depends on its level of expression. In this study, we speculated that Bcl-xES sequesters various proapoptotic proteins, thus impeding the activation and oligomerization of Bax into active high molecular weight complexes. A recent investigation indicated that Bcl-2 and Bcl-xL sequestered BH3 domain-only proteins, preventing the activation of Bax or Bak . Although all possible protein-protein interactions were not addressed in this study, we showed that Bax oligomerization was delayed after CPT treatment in Namalwa/Bcl-xES-transfected Figure 7 Effects of Bcl-xES on Apaf-1 oligomerization and procaspase-9 activation. (a) FPLC elution profiles of Apaf-1 and caspase-9 from control and drug-treated Namalwa (upper panels) and Namalwa/Bcl-xEs cells (lower panels) on Superose 6-HR 16/50, as described in Materials and methods. Cellular extracts were prepared at the indicated times from 5 Â 10 8 control and drug-treated cells. Lysis buffer contained 25 mM HEPES (pH 7.4), 300 mM NaCl, 0.2 mM DTT, 2% CHAPS, 6 mM sucrose and a cocktail of protease inhibitors. To avoid Apaf-1 self-oligomerization during the lysis procedure, 10 mM ATP-gS was added. The elution peaks of the molecular weight standards (kDa) are indicated by vertical arrows. Following chromatography, 80 ml of each fraction was run on SDS-PAGE and electrotransferred. Blots were revealed using anti-Apaf-1 monoclonal antibody and anti-caspase-9 monoclonal antibody that recognized the precursor and an active cleaved fragment (indicated by arrows), and visualized by enhanced chemiluminescence and film exposure. (b) Co-immunoprecipitation of Bcl-xES and Apaf-1. Co-immunoprecipitation experiments on control and transfected Namalwa/Bcl-xES cells were performed with anti-HA antibody (Roche Molecular Biochemicals, clone 12CA5), at the indicated times after 30-min treatment with 0.1 mM CPT (upper panels) or 1.0 mM CPT (lower panels). Immunoblots were revealed using anti-Apaf-1 monoclonal antibody (R&D Systems, clone 94408.11) and anti-HA monoclonal antibody (Roche Molecular Biochemicals, clone 12CA5) before enhanced chemiluminescence and film exposure. (C) Bcl-xES(DTM) interferes with procaspase-9 activation in a cell-free assay. U-937 cell-free extracts were incubated with cytochrome c/dATP in the absence or presence of different amounts of purified recombinant BclxES(DTM) protein. Cleavage of Ac-LEHD-AFC was monitored as initial velocities. The results are expressed as percentages of relative enzyme activity, using the formula ½ðVi À Vo=Va À VoÞÂ100, where Vi is the initial velocity measured in the presence of various fixed amounts of inhibitor, Vo is the basal initial velocity measured in unactivated control extract, and Va is the initial velocity measured in activated extracts in the absence of inhibitor. Data points represent the means7s.d. of four independent experiments cells compared to parental Namalwa cells. In addition, we observed in co-immunoprecipitation experiments that Bcl-xES binds directly to Bax and Bak. Similar findings have been made reported in Hela cells exposed to staurosporine or ultraviolet irradiation and in rat kidney proximal tubule cells treated with carbonyl cyanide-m-chlorophenylhydrazone (Mikhailov et al., 2001) , using different biochemical techniques, including gel filtration chromatography and protein crosslinking. Bax oligomer formation and insertion into the mitochondrial membrane were inhibited in the presence of antiapoptotic Bcl-2 protein in these studies Mikhailov et al., 2001) . Employing confocal microscopy and immunogold-labeling electron microscopy, others have also observed that Bcl-xL completely inhibited the formation of Bax and Bak high molecular weight clusters in staurosporine-treated cells (Nechushtan et al., 2001) . Thus, it appeared in our study that the delay of cytochrome c release in Namalwa/Bcl-xES-transfected cells could be attributed to the effect of Bcl-xES on Bax activation and oligomer formation.
Bcl-xES showed strong interaction with Apaf-1 in yeast two-hybrid assay. In C. elegans, the prosurvival Ced-9 binds and sequesters Ced-4, but also forms a ternary complex with Ced-3, preventing Ced-4 oligomerization and Ced-3 activation (Chinnaiyan et al., 1997; Seshagiri and Miller, 1997; Spector et al., 1997; Wu et al., 1997a, b; Chaudhary et al., 1998) . Initial studies revealed similar interactions in mammalian cells between some antiapoptotic members of the Bcl-2 family, including Bcl-xL, Bcl-2 and Diva, and Apaf-1 Huang et al., 1998; Inohara et al., 1998; Pan et al., 1998; Song et al., 1999) . Bcl-xL, Bcl-2 and Boo/Diva binding to Apaf-1 appeared to inhibit cytochrome c-dependent Apaf-1 oligomerization and procaspase-9 activation Inohara et al., 1998; Pan et al., 1998; Song et al., 1999) . However, contrary observations have also been reported (Moriishi et al., 1999; Conus et al., 2000; Haraguchi et al., 2000; Hausmann et al., 2000; Newmeyer et al., 2000) . In addition, heat shock protein 70 (HSP70) was shown to interact directly with Apaf-1, while HSP27 was reported to bind cytochrome c, and both could prevent Apaf-1 oligomerization and subsequent caspase-9 activation (Garrido et al., 1999; Beere et al., 2000; Bruey et al., 2000; Saleh et al., 2000) . Using co-immunoprecipitation assays, we found an interaction between Bcl-xES and Apaf-1 in Namalwa cells. The association between the two proteins was also detected in cells treated with 0.1 mM CPT, but was diminished when they were treated with 1.0 mM CPT. To further elaborate these observations, we monitored the kinetics of Apaf-1 oligomerization and caspase-9 activation in Namalwa/ Bcl-xES-transfected cells compared to wild-type Namalwa cells after CPT treatment. In untransfected Namalwa cells, the elution profiles of Apaf-1 showed a prominent shift of the protein toward fractions of higher molecular weight 2 h after 0.1 mM CPT treatment, and Apaf-1 oligomerization coincided with the appearance of active caspase-9 fragments. In contrast, in Namalwa/Bcl-xEStransfected cells, the elution profiles of Apaf-1 after 0.1 mM CPT treatment presented neither Apaf-1 oligomerization nor procaspase-9 activation, even 4 h after drug treatment. The lack of Apaf-1 oligomerization in Namalwa/Bcl-xES cells was possibly caused by two phenomena. First, as discussed above, Bcl-xES delayed Bax oligomer formation and cytochrome c release, an essential cofactor required for Apaf-1 oligomerization. Thus, the lack of cytochrome c release is consistent with the lack of Apaf-1 oligomerization. However, Bcl-xES binding to Apaf-1 could possibly interfere with Apaf-1 oligomerization, even in the presence of cytochrome c. The results obtained in a cell-free system where caspase-9 activity, initiated by adding cytochrome c and dATP, is inhibited by adding various amounts of Bcl-xES are also consistent with this hypothesis. Controversial data have been reported by different investigators using a similar cell-free system Pan et al., 1998; Hausmann et al., 2000) . The reasons behind these differences are unknown. Perhaps, such contradictory results indicate that other factors present or absent in these extracts contribute to or interfere with the action of antiapoptotic proteins utilized in these assays. Perhaps the level of expression of other Bcl-2 family members and/or of various HSP and/or of Aven, a protein that binds to both Bcl-xL and Apaf-1, should be considered (Garrido et al., 1999; Beere et al., 2000; Bruey et al., 2000; Saleh et al., 2000) . Nevertheless, other experiments will be required to identify these putative factors.
In summary, we have identified a novel Bcl-x member expressed in various human tissues and cancer cell lines. Bcl-xES has antiapoptotic activity in Namalwa cells. Our results indicated that Bcl-xES delayed drug-induced apoptosis by disturbing the formation of Bax oligomers, thus preventing cytochrome c release and Apaf-1 oligomerization. In addition, the interaction of BclxES with Apaf-1 suggested that Bcl-xES could also sequester Apaf-1, preventing procaspase-9 activation.
Materials and methods
Chemicals
Radioactive precursors [a-32 P]-dCTP (43000 Ci/mmol), [a- 
CDNA cloning of human Bcl-xES
Human Bcl-xES cDNA was cloned by reverse transcriptionpolymerase chain reaction (RT-PCR) from mRNA obtained from human HL-60 cells, using specific adapter primers containing NotI sequences at the ATG start codon (5 0 -primer GCGGCCGCATGTCTCAGAGCAACCGGGAG) and TGA stop codon (complementary 3 0 -primer GCGGCCGCTCATTTCCGACTGAAGAGTGA). The amplified fragment was first cloned in pCRII vector (InVitrogen, Carlsbad, CA, USA) and then subcloned at the NotI restriction site in the eucaryotic expression vector pCEP4 (InVitrogen) modified to include consensus Kozak and hemagglutinin epitope Tag sequences (HA-tag) (Schmitt et al., 1998a (Schmitt et al., , b, 2000 . All vectors were sequenced by ALF DNA sequencer (LKB-Pharmacia Biotech, Upsalla, Sweden). Restriction and modification enzymes were purchased either from Pharmacia Biotech or Gibco-BRL Life Technologies (Grand Island, NY, USA).
Cell culture, transfection and DNA labeling All cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA) and grown in suspension culture at 371C in the presence of 5% CO 2 in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin. Cell culture products were purchased from Gibco-BRL Life Technologies. Cesium chloride-purified pCEP4-HA-Bcl-xES and pCEP4-HA-mock vectors were transfected in Namalwa cells by electroporation at 0.27 kV (Gene Pulser, BioRad, Hercules, CA, USA). To obtain stable transfected lines, the cells were grown under hygromycin B selection at 1.5 mg/ml for 3 months prior to the experiments, as described elsewhere (Schmitt et al., 1998a (Schmitt et al., , b, 2000 . For DNA labeling, Namalwa cells were grown with [
14 C]-thymidine (0.02 mCi/ml) for 24 h, then chased overnight in isotope-free medium prior to drug treatment (Schmitt et al., 1998a (Schmitt et al., , b, 2000 .
Expression studies by RT-PCR and ribonuclease protection assays
Total RNA was isolated from exponentially growing cells with TRIzol s reagent according to the manufacturer's procedure (Gibco-BRL Life Technologies), and first-strand cDNA was synthesized from 2.0. mg of RNA, employing Moloney murine leukemia virus RT (2.5 U) (Perkin-Elmer Biosystem, Branchburg, NJ, USA) with oligo dT(16) priming. cDNAs from normal tissues were procured from InVitrogen, bone marrow samples were acquired from biopsies of acute lymphocytic leukemia patients (Dr Yves Theoret, Hoˆpital Sainte-Justine, Montreal, Que., Canada) and colon adenocarcinoma samples were obtained through the US National Cancer Institute's Cooperative Human Tissue Network. Bcl-x cDNAs were amplified with 50 ng of the 5 0 -primer ATGTCTCAGAG-CAACCGGGAG and 50 ng of the complementary 3 0 -primer TCATTTCCG ACTGAAGAGTGA in a reaction mixture containing 200 mM dNTPs, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), and 0.5 U Taq DNA polymerase (Perkin-Elmer Biosystem). The reaction mixtures were heated for 5 min at 951C and amplified for 30 cycles with denaturation at 951C for 1 min, annealing at 551C for 45 s and extension at 721C for 45 s. The amplified products were electrophoresed on 1.6% agarose gel in Tris-acetate buffer (pH 8.0) and transferred by capillarity to GeneScreen nylon membranes (Dupont-NEM Research Products, Boston, MA, USA). After DNA denaturation and fixation, blots were hybridized with purified human Bcl-xL cDNA probe labeled with [a- 32 P]-dCTP by a random priming procedure. Hybridizations were undertaken overnight at 421C in a solution containing 2 Â SSC, 2 Â Denhart, 2% (w/v) SDS, 50% (v/v) formamide and 100 mg/ml salmon sperm DNA. The blots were washed for 30 min at 421C in 0.1 Â SSC and 0.1% (w/v) SDS, then for 45 min at 681C in 0.05 Â SSC and 0.05% (w/v) SDS. DNA was visualized by autoradiography on Kodak X-AR film. Isoform expression was confirmed by RNase protection assays in some samples. Specific [a- 32 P]-dUTP-labeled Bcl-xES cRNA probes were generated with the MAXIscript SP6 and T7 s kit (Ambion, Inc., Austin, TX, USA) using, as template, the StyI linearized pCRII plasmid containing Bcl-xES. The probes were eluted from 5% polyacrylamide urea gel after electrophoresis, hybridized with total RNA (10 mg) for 16 h, then digested with RNase A and T1. The protected fragments were precipitated and then separated on 5% polyacrylamide urea gel. RNA double strands were visualized by autoradiography on Kodak X-AR film. b-actin served as controls in the RT-PCR and RNase protection assays. Relative densitometry analysis of autoradiographs was based on integrated density values (IDV) using an AlphaImager 2000 scanner (Alpha innovatech, San Jose, CA, USA).
Subcellular fractionation, immunoprecipitation, crosslinking and Western blot analysis
To prepare whole-cell protein extracts, control and CPTtreated cells were collected by centrifugation and then homogenized in lysis buffer containing 50 mM Tris (pH 7.4), 120 mM NaCl, 1% (v/v) Triton X-100, 1 mM sodium orthovanadate, 2 mM phenylmethylsulfonyl fluoride, 5 mM sodium pyrophosphate, a cocktail of protease inhibitors (Complete t , Roche Molecular Biochemicals, Laval, Que., Canada) and 10 mg/ml lactacystin. The supernatants were collected after centrifugation (10 000 g for 15 min at 41C). For subcellular fractionation, the cells were first swelled in deionized water for 4 min on ice. The samples were adjusted to 220 mM mannitol, 70 mM sucrose, 5 mM HEPES, pH 7.4, and 1.0 mM EDTA (isotonic buffer), then dounced briefly on ice. Nuclei (1000 g, 15 min) and mitochondria (10 000 g, 15 min) were pelleted by sequential differential centrifugation. The supernatants were clarified further by centrifugation at 100 000 g for 60 min (S-100 fraction). For standard co-immunoprecipitations, cells were collected by centrifugation, washed twice with ice-cold PBS, and then homogenized in lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM NaVO 4 , 1% BSA, 1% nonidet P-40, 2 mM PMSF, 1 mg/ml aprotinin) at 41C for 30 min. The extracts were centrifuged and supernatants collected.
For co-immunoprecipitation experiments performed from mitochondria-enriched fractions, untreated and CPT-treated Namalwa cells were swelled in deionized water for 4 min on ice, and the samples adjusted in isotonic buffer as above. The cells were disrupted by passing the samples 30-fold through a 26G 3/8 needle, with subsequent centifugation at 1000 g for 15 min. The supernatant was centrifuged at 10 000 g for 15 min to obtain a mitochondria-enriched pellet. This mitochondrial pellet was resuspended in isotonic buffer containing 5 mM DSP crosslinker agent, and incubated for 30 min by rotation at room temperature. The crosslinking reaction was quenched by the addition of Tris (pH 7.5) to a final concentration of 50 mM, and incubated for an additional 15 min. After centrifugation at 10 000 g for 15 min, the supernatant containing DSP was discarded, and the mitochondrial pellet was lysed in buffer containing 25 mM HEPES (pH 7.5), 300 mM NaCl, 0.2 mM DTT, 2% (w/v) CHAPS, 5% sucrose (w/v), a cocktail of protease inhibitors (Complete s , Roche Molecular Biochemicals) and 10 mg/ml lactacystin. After lysis and a final centrifugation step (10 000 g for 15 min at 41C), the supernatant was used as a mitochondria-enriched fraction.
Specific anti-HA monoclonal antibodies were added for 3 h, and immunocomplexes were captured and precipitated with protein A/G-sepharose (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). Antibodies against the peptide epitope derived from the HA protein of human influenza virus (clone 12CA5) were obtained from Roche Molecular Biochemicals, anti-Bcl-x mouse antibody (clone 44) was purchased from BD Transduction Laboratories (Mississauga, Ont., Canada), anticytochrome c mouse monoclonal antibody (clone 7H8.2C12) and anti-caspase-9 mouse monoclonal antibody (clone 2-22) were from BD PharMingen (Mississauga, Ont., Canada), antiBax rabbit polyclonal antibody (N-20) was from Santa Cruz Biotechnology, anti-Bak rabbit polyclonal antibody (06-536) was from Upstate Biotechnology, and anti-Apaf-1 monoclonal antibody (clone 94408.11) was from R&D Systems (Minnesotta, MN, USA). In samples where the crosslinker agent was used, the covalent amide bonds created were cleaved by incubating the immunocomplexes in Leammli buffer containing 75 mM DTT for 30 min at 371C. After SDS-PAGE, the composition of the immunocomplexes was analysed by Western blotting. Enhanced chemiluminescence detection of peroxidase-labeled secondary antibodies was performed with Amersham-Pharmacia Biotech (Piscataway, NJ, USA) reagents.
DNA fragmentation assay
DNA filter elution assays were designed to monitor and quantitate DNA fragmentation associated with apoptosis (Bertrand et al., 1991) . 5 Â 10 6 [ 14 C]-Thymidine-labeled cells were loaded onto protein-adsorbing filters (vinyl/acrylic copolymer filters, Metricel membrane, 0.8-mm pore size, 25-mm diameter, Gelman Sciences, Inc., Ann Arbor, MI, USA), and washed with 5 ml of PBS. As soon as the washing solution dripped through by gravity, lysis was performed with 5 ml of lysis solution (2% SDS, 0.04 M EDTA, pH 10.0). After the lysis solution had dripped through by gravity, the filters were washed with 5 ml of 0.02 M EDTA (pH 10.0), and then processed as described earlier (Bertrand et al., 1991) . Briefly, they were placed in scintillation vials to which 1.0 ml of 1 N HCl was added. The vials were sealed and heated for 1 h at 601C to depurinate the DNA. Then, 2.5 ml of 0.4 N NaOH was added and allowed to stand for 1 h at room temperature to release labeled DNA from the filters. Radioactivity was counted in each fraction (loading wash, lysis, EDTA wash, filter) by liquid scintillation spectrometry. DNA fragmentation was determined as the DNA fraction in the loading wash fraction þ lysis fraction þ EDTA wash fraction relative to total DNA (loading wash þ lysis þ EDTA wash þ filter). The results were expressed as the percentage of DNA fragmented in treated cells compared to DNA fragmented in untreated cells (background) according to the formula ðF À F 0=1 À F0ÞÂ100 where F and F0 represent DNA fragmentation in treated and control cells, respectively.
LEHDase and DEVDase activity measurement
Cytosolic extracts were prepared by washing control and transfected Namalwa cells twice by centrifugation/resuspension in 10 ml ice-cold PBS (without Ca 2 þ and Mg 2 þ ). The cells were then homogenized at 41C for 30 min in lysis buffer containing 100 mM HEPES (pH 7.5), 5 mM EDTA, 5 mM DTT, 20% glycerol and 0.1% NP-40. The samples were centrifuged (13 000 g for 10 min at 41C), and supernatants collected as cytosolic extracts. Caspase activities were measured by monitoring fluorescence continuously in a dual luminescence LS 50B fluorometer (Perkin-Elmer Biosystem) at an excitation wavelength of 400 nm and an emission wavelength of 505 nm for the substrate Ac-LEHD-AFC, and an excitation wavelength of 380 nm and an emission wavelength of 460 nm for Ac-DEVD-AMC. Reactions were carried out in cuvettes, and temperature was maintained at 371C with a water-jacketed sample compartment. The assay mixture contained 100 mM HEPES (pH 7.5), 20% (v/v) glycerol, 5 mM DTT, 5 mM EDTA and 500 mM Ac-LEHD-AFC or 200 mM Ac-DEVD-AMC. In all, 200 mg of total cell extracts were used per assay. Enzyme activities were determined as initial velocities and expressed as relative intensity/min/mg.
Yeast two-hybrid system
The MatchMaker LexA s two-hybrid system (Clontech Laboratories, Inc., Palo Alto, CA, USA) was employed according to the manufacturer's instructions. Bcl-xES and Bcl-xL deleted of their TM domains (Bcl-xES(DTM), Bcl-xL(DTM)) and the deletion mutants Bcl-xES(DBH2DTM) and BclxES(DBH4DTM) were subcloned in the two-hybrid plasmid pLexA vector. All other cDNAs were cloned in the two-hybrid plasmid pB42AD, as described previously (Schmitt et al., 2000) . Sequential transformations were conducted by the lithium acetate method in yeast strain EGY48, and the cells were plated on histidine-deficient (for pLexA marker), tryptophan-deficient (for pB42AD marker) and histidine/ tryptophan/leucine-deficient (for LEU2 reporter gene assay) minimal SD induction/selection media. pLexA p53, pLex Lam and pB42AD T from Clontech Laboratories served as positive and negative controls.
Gel filtration chromatography
Gel filtration chromatography was performed on a Superose 6-HR 16/50 column (Amersham-Pharmacia Biotech) connected to a FPLC system (LKB-Pharmacia Biotech) and calibrated with gel filtration standard proteins (Amersham Pharmacia Biotech), including ribonuclease A (13.7 kDa, 16.4 Å ), chymotrypsinogen A (25 kDa, 20.9 Å ), ovalbumin (43 kDa, 30.5 Å ), albumin (67 kDa, 35.5 Å ), aldolase (158 kDa, 48.1 Å ), catalase (232 kDa, 52.2 Å ), apoferritin (440 kDa, 61.0 Å ) and thyroglobulin (669 kDa, 85 Å ). Void volume corresponded to the elution of Blue Dextran 2000. Conditions were based on previously described methods with modifications (Cain et al., 1999; Antonsson et al., 2001) . The equilibration, lysis and elution buffer contains 25 mM HEPES (pH 7.5), 300 mM NaCl, 0.2 mM DDT, 2% (w/v) CHAPS, 5% sucrose (w/v) and a cocktail of protease inhibitors (Complete s , Roche Molecular Biochemicals). To avoid Apaf-1 self-oligomerization during the lysis procedure, 10 mM ATP-gS was added to the lysis buffer. Cellular extracts were prepared from 5 Â 10 8 control and CPT-treated cells. The soluble fractions after lysis (30 min on ice) and centrifugation (10 000 g for 15 min at 41C) were loaded onto the column in 500-ml volume. Elutions were performed at a flow rate of 500 ml/min, and fractions of 2.5 ml were collected at 5-min intervals. After chromatography, 80-ml aliquots of each fraction were analysed by Western blotting.
